Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis.

doi:10.1111/bjh.14695

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis.

British journal of haematology - 1 Aug 2017

Héritier Sébastien, Hélias-Rodzewicz Zofia, Lapillonne Hélène, Terrones Nathalie, Garrigou Sonia, Normand Corinne, Barkaoui Mohamed-Aziz, Miron Jean, Plat Geneviève, Aladjidi Nathalie, Pagnier Anne, Deville Anne, Gillibert-Yvert Marion, Moshous Despina, Lefèvre-Utile Alain, Lutun Anne, Paillard Catherine, Thomas Caroline, Jeziorski Eric, Nizard Philippe, Taly Valérie, Emile Jean-François, Donadieu Jean

Abstract excerpt

The BRAFV600E mutation is reported in half of patients with Langerhans cell histiocytosis (LCH). This study investigated the detection of the BRAFV600E allele in circulating cell-free (ccf) DNA in a paediatric LCH cohort. Children with BRAFV600E -mutated LCH were investigated to detect ccf BRAFV600E at diagnosis (n = 48) and during follow-up (n = 17) using a picolitre-droplet digital PCR assay. At diagnosis, ccf...

Topics

Adolescent
Alleles
Biomarkers
Cell-Free System
Child
Child, Preschool
Drug Monitoring
Drug Therapy, Combination
Female

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Follow-Up Studies

Glucocorticoids

Histiocytosis, Langerhans-Cell

Humans

Indoles

Infant

Male

Mutation

Prognosis

Source

Open in PubMed

Identifiers

PMID: 28444728
DOI: 10.1111/bjh.14695

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-28444728-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis.PMID 28444728Read ↗

Vemurafenib provides a rapid and robust clinical response in paediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease based on ddPCR using cell-free circulating DNASemantic proximity Read ↗

Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing.Semantic proximity Read ↗

Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.Semantic proximity Read ↗

BRAF V600E Mutation in Cell-Free DNA, Rather than in Lesion Tissues, at Diagnosis Is An Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis.Semantic proximity Read ↗

BRAF-V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first-line therapy.Semantic proximity Read ↗

Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.Semantic proximity Read ↗

Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.Semantic proximity Read ↗

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.Semantic proximity Read ↗

BRAF Mutated LCH: Diagnosis and Treatment Challenges - A High-Risk Case Presentation and Discussion.Semantic proximity Read ↗

Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis.Semantic proximity Read ↗

Refractory multisystem Langerhans cell histiocytosis in an infant: use of vemurafenib as a therapeutic option.Semantic proximity Read ↗

Advances in our understanding of genetic markers and targeted therapies for pediatric LCH.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.